Only days after highlighting abstracts for its upcoming presentations at the American Society of Hematology (ASH) meeting in Atlanta and CEO Ron Squarer's assertion that his firm was "evolving into a late-stage development company" with five programs moving toward pivotal decisions in 2013, Array BioPharma Inc. is doubling its cash position with a $65.7 million public offering. Read More
It wasn't the first time that a deal by GlaxoSmithKline plc left Wall Street unsatisfied and ultimately fizzled, but the severing of XenoPort's tie with the pharma giant leaves the biotech in fairly good shape: full rights to Horizant (gabapentin enacarbil) and $20 million in new equity money. Read More
Think "rare, pediatric diseases" and you tend to think "drug cocktail that changes over time" and "almost impossible to get enough investors, given the risk vs. return, not to mention the long development period." Read More
• Jazz Pharmaceuticals plc, of Dublin, Ireland, reported third-quarter revenue of $176 million, with net income coming in at $33.6 million, or 56 cents per share. Based on analyst estimates, revenue soundly beat expectations, while earnings-per-share numbers came up short. Read More
• Pluristem Therapeutics Inc., of Haifa, Israel, issued a release late Thursday commenting on an article published Wednesday by Bloomberg reporting that a patient given the firm's PLX cell treatment had died after the company said her life had been saved. Read More
• Biotron Ltd., of Sydney, Australia, started a Phase II trial with its lead antiviral drug candidate, BIT225 in patients that are co-infected with both HIV and hepatitis C virus (HCV). Read More
• GenSpera Inc., of San Antonio, presented interim data from its ongoing Phase I trial of G-202 in patients with advanced solid tumor cancers. The main conclusions are that G-202 appeared to be well tolerated when administered via the recommended dosing regimen and that it should be evaluated in Phase II studies. Read More
• Chiromics LLC, of Princeton, N.J., is collaborating with London-based GlaxoSmithKline plc to discover new classes of small molecules against certain biological targets. Chiromics' compound collections are assembled using its core chemical technology referred to as cascade catalysis. Read More
• Novo Nordisk A/S, of Bagsvaerd, Denmark, said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 8-4 in favor of approving insulin degludec and insulin degludec/insulin aspart with a post-approval cardiovascular outcomes trial commitment. Read More
Researchers at the University of Wisconsin at Madison mapped changes to the mitochondrial proteome and its phosphorylation in lean and obese mice at different ages, as well as during fasting and refeeding after a fast. Read More
